Investor’s Watch List – Aldeyra Therapeutics Inc (NASDAQ:ALDX)
On Thursday, Shares of Aldeyra Therapeutics Inc (NASDAQ:ALDX) lost -2.14% to $5.04. Trading volume recorded for this company was about 38,581 shares as contrast to its average volume of 37,794 shares. The stock’s intraday range was $4.90 to $5.30. The company has the total of 14.79M outstanding shares, while its market capitalization is about $73678.
Aldeyra Therapeutics, Inc. ( NASDAQ : ALDX ) (Aldeyra), a biotechnology company focused mainly on the development of new products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes, today declared its financial results for the year ended December 31, 2016.
“2016 was a productive year for Aldeyra, underlined by positive data from our late-stage clinical programs in allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson Syndrome,” commented Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra. “We look forward to building upon our accomplishments from last year as we advance our clinical programs, two of which are predictable to begin Phase 3 studies in 2017. In addition, we expect to initiate a new clinical program in Dry Eye Syndrome.”
Year Ended December 31, 2016 Financial Review:
For the year ended December 31, 2016, Aldeyra stated a net loss of about $18.70M contrast to a net loss of about $12.10M for the year ended December 31, 2015. Basic and diluted net loss per share was $1.65 for the year ended December 31, 2016 contrast to $1.40 per share for the same period in 2015. Losses have resulted from the costs of Aldeyra’s clinical trials and research and development programs, in addition to from general and administrative expenses.
Research and development expenses were $13.20M for the year ended December 31, 2016 contrast to $7.60M for the same period in 2015. The increase of $5.60M is mainly related to the increase in research and development expenditures, counting manufacturing, preclinical and clinical development costs, and a boost in personnel costs.
General and administrative expenses were $5.50M for the year ended December 31, 2016, contrast to $4.40M for the year ended 2015. The increase of $1.10M is mainly related to a boost in legal costs, rent, consulting costs, and personnel costs.
In 2016, total operating expenses were about $18.70M for the year contrast to total operating expenses of about $12.0M in the prior year.
Technical Analysis:
The stock price is going up to its 52-week low with +28.17% and lower from its 52-week high with -38.34%. The stock has shown its weekly performance of 2.10% and monthly performance stands at 2.02%. The stock price is moving down from its 200 days moving average with -11.33% and downward from 50 days moving average with -1.73%.
Analyst recommendation for this stock stands at 1.60.